Hematologics

3161 Elliott Avenue, Suite 200, Seattle, WA 98121 Phone (800) 860-0934 Fax: (206) 223-5550 www.hematologics.com

AML MRD Identified by ΔN:™ (Difference from Normal) Flow Cytometry at 0.04% confirmed by *FACS-FISH*

Clinical History/Indications: A patient with a clinical history of acute myeloid leukemia had a bone marrow aspirate submitted for Measurable Residual Disease(MRD) detection.



Analysis/Conclusions: The **Δ:™** ***Flow Cytometry*** findings reveal: 7.4% lymphocytes, 6.1% monocytes, 81% myeloid forms (all stages of maturation), 0.05% lymphoblasts, and 0.04% abnormal myeloid progenitor cells consistent with residual AML. Cell enrichment, by ***Fluorescent Activated Cell Sorting (FACS*)**, of CD34 positive cells that included the abnormal cell population was followed by ***FISH (FACS-FISH)***.

FACS-FISH



FISH (fluorescence in situ hybridization) **Result: Abnormal Monosomy 7**

Interphase FISH (fluorescence in situ hybridization) was performed using the D7S522/CEP 7 probe set to assess the CD34+ flow cytometric sorted cell population for the presence of monosomy 7. During the analysis of 200 interphase cells with the D7S522/CEP 7 probe set showed a 1R1G pattern (see image) in **25%** of the CD34+ cells examined, consistent with monosomy 7.